company overview


Cortice Biosciences is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic indications with urgent unmet medical need.

Microtubule stabilizing taxoids for treatment of brain cancers and CNS disease

Our lead drug candidate, TPI 287, is a novel microtubule stabilizing taxoid with the unique property of being able to readily penetrate the blood-brain barrier. Accordingly, we are developing TPI 287 for treatment of cancers of the brain, including glioblastoma and secondary brain metastases.

Given the potential of microtubule stabilization as a therapeutic approach for neurodegenerative diseases known as tauopathies, we are also developing TPI 287 for treatment of progressive supranuclear palsy, corticobasal dementia, and Alzheimer's disease.